Overview
- Editors:
-
-
Maryse Picher
-
and Treatment Center, Cystic Fibrosis Pulmonary Research and T, University of North Carolina, Chapel Hill,, USA
-
Richard C. Boucher
-
University of North Carolina, - Cystic Fibrosis Pulmonary Research and, CHAPEL HILL, USA
- Pivotal Roles of Purinergic Signaling in Airway Defenses
- Disease-Specific Aberrances in Sputum Adenosine Regulation
- Diagnostic Value of AMP-Mediated Bronchoconstriction
- Distinct Therapies for Acute Lung Injury and Chronic Lung Diseases
- Critical Analysis of Past and Current Clinical Trials
- Includes supplementary material: sn.pub/extras
Access this book
Other ways to access
Table of contents (9 chapters)
-
Front Matter
Pages i-xvii
-
- Eduardo R. Lazarowski, Juliana I. Sesma, Lucia Seminario, Charles R. Esther Jr., Silvia M. Kreda
Pages 1-15
-
-
- Guilherme J. M. Garcia, Maryse Picher, Peiying Zuo, Seiko F. Okada, Eduardo R. Lazarowski, Brian Button et al.
Pages 51-74
-
- Charles R. Esther Jr., Neil E. Alexis, Maryse Picher
Pages 75-93
-
- Andreas Schmid, Lucy A. Clunes, Mathias Salathe, Pedro Verdugo, Paul Dietl, C. William Davis et al.
Pages 95-138
-
- Albert van der Vliet, Peter F. Bove
Pages 139-157
-
- Michael Koeppen, Francesco Di Virgilio, Eric T. Clambey, Holger K. Eltzschig
Pages 159-193
-
- Linda F. Thompson, Maryse Picher, Michael R. Blackburn
Pages 195-234
-
- Stephen Tilley, Jon Volmer, Maryse Picher
Pages 235-276
-
Back Matter
Pages 277-280
About this book
We proudly present the first book to integrate all aspects of purinergic signaling in the respiratory system. The first chapters introduce basic notions of purinergic pharmacology and metabolism, which allows readers from all scientific backgrounds to fully grasp the importance of these signaling networks for airway defenses, including mucociliary clearance and inflammatory responses. Then, chapters are devoted to the groundbreaking discovery that chronic respiratory diseases, including asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD), present specific aberrances in purinergic signaling which essentially drive lung complications. The last chapters describe the animal models used to investigate purinergic signaling in respiratory diseases, and the therapeutic applications developed by the pharmaceutical industry based on receptor agonists/antagonists and metabolic correctors. This highly comprehensive manuscript constitutes an invaluable tool for beginners and experts to follow the rapidly evolving research field of purinergic signaling. Furthermore, the critical analysis of past clinical protocols should facilitate the identification of potent therapeutic targets, and provide a better understanding of the data acquired in current clinical trials.
Editors and Affiliations
-
and Treatment Center, Cystic Fibrosis Pulmonary Research and T, University of North Carolina, Chapel Hill,, USA
Maryse Picher
-
University of North Carolina, - Cystic Fibrosis Pulmonary Research and, CHAPEL HILL, USA
Richard C. Boucher
